DK1793671T3 - Anvendelse af memantin (namenda) til behandling af autisme, tvangstilstand og impulsivitet - Google Patents
Anvendelse af memantin (namenda) til behandling af autisme, tvangstilstand og impulsivitetInfo
- Publication number
- DK1793671T3 DK1793671T3 DK05808933.5T DK05808933T DK1793671T3 DK 1793671 T3 DK1793671 T3 DK 1793671T3 DK 05808933 T DK05808933 T DK 05808933T DK 1793671 T3 DK1793671 T3 DK 1793671T3
- Authority
- DK
- Denmark
- Prior art keywords
- memantine
- treatment
- autism
- namenda
- impulsivity
- Prior art date
Links
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004640 memantine Drugs 0.000 title abstract 3
- 206010003805 Autism Diseases 0.000 title abstract 2
- 208000020706 Autistic disease Diseases 0.000 title abstract 2
- 229940033872 namenda Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000012202 Pervasive developmental disease Diseases 0.000 abstract 1
- 208000029560 autism spectrum disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Saccharide Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Chemical And Physical Treatments For Wood And The Like (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61153404P | 2004-09-20 | 2004-09-20 | |
| PCT/US2005/033467 WO2006034187A2 (en) | 2004-09-20 | 2005-09-19 | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1793671T3 true DK1793671T3 (da) | 2011-08-22 |
Family
ID=36090565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05808933.5T DK1793671T3 (da) | 2004-09-20 | 2005-09-19 | Anvendelse af memantin (namenda) til behandling af autisme, tvangstilstand og impulsivitet |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US8461148B2 (da) |
| EP (1) | EP1793671B1 (da) |
| JP (1) | JP5289765B2 (da) |
| AT (1) | ATE506945T1 (da) |
| AU (1) | AU2005286943A1 (da) |
| CA (1) | CA2580619C (da) |
| DE (1) | DE602005027714D1 (da) |
| DK (1) | DK1793671T3 (da) |
| ES (1) | ES2367868T3 (da) |
| WO (1) | WO2006034187A2 (da) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7456224B2 (en) | 2004-04-05 | 2008-11-25 | Forest Laboratories Holdings, Ltd. | Method for treating autism |
| WO2006094674A1 (en) * | 2005-03-07 | 2006-09-14 | Michael Hermanussen | Nmda receptor antagonists in the medical intervention of metabolic disorders |
| US9427419B2 (en) | 2005-09-12 | 2016-08-30 | Abela Pharmaceuticals, Inc. | Compositions comprising dimethyl sulfoxide (DMSO) |
| CA2622204C (en) | 2005-09-12 | 2016-10-11 | Abela Pharmaceuticals, Inc. | Systems for removing dimethyl sulfoxide (dmso) or related compounds, or odors associated with same |
| WO2007033180A1 (en) * | 2005-09-12 | 2007-03-22 | Abela Pharmaceuticals, Inc. | Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds |
| WO2007061868A2 (en) * | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| WO2008063847A2 (en) * | 2006-11-03 | 2008-05-29 | Forest Laboratories Holdings Limited | Method for treating autism |
| EP2170310A4 (en) * | 2007-06-29 | 2010-06-23 | Orchid Chemicals & Pharm Ltd | FAST-DISSOLVING COMPOSITIONS OF MEMANTINE HYDROCHLORIDE |
| WO2009035473A2 (en) * | 2007-09-13 | 2009-03-19 | Sanfilippo Louis C | Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders |
| EP2111858A1 (en) * | 2008-04-25 | 2009-10-28 | EPFL Ecole Polytechnique Fédérale de Lausanne | Novel treatment for alzheimer's disease |
| BRPI0921494A2 (pt) | 2008-11-03 | 2018-10-30 | Prad Reasearch And Development Ltd | método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração. |
| CN102070463A (zh) * | 2009-06-11 | 2011-05-25 | 辽宁利锋科技开发有限公司 | 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用 |
| AU2010313253B2 (en) | 2009-10-30 | 2015-02-19 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) formulations to treat osteoarthritis |
| WO2011123695A1 (en) * | 2010-03-31 | 2011-10-06 | Abela Pharmaceuticals, Inc. | Dimethy sulfoxxide (dmso) formulations for treating autism |
| BR112013018898B1 (pt) * | 2011-01-27 | 2021-10-05 | Neuren Pharmaceuticals Limited | Uso de ácido glicil-l-2-metilprolil-l-glutâmico e análogos do mesmo para o tratamento de transtornos do espectro do autismo |
| MX2014012374A (es) * | 2012-04-14 | 2015-04-17 | Intra Cellular Therapies Inc | Compuestos organicos. |
| US20130296430A1 (en) * | 2012-05-03 | 2013-11-07 | Antonio Hardan | Compositions and methods for treating autism and autism spectrum disorder |
| EP2928300A4 (en) * | 2012-11-28 | 2016-07-13 | Neuren Pharmaceuticals Ltd | TREATMENT OF AUTISTIC DISEASES WITH GLYCYL-L-2-METHYLPROLYL-L-GLUTAMINE ACID |
| KR101424514B1 (ko) | 2013-01-02 | 2014-07-31 | 건국대학교 산학협력단 | 선천성 발프로산 노출 증후군 치료제로서의 메만틴의 용도 |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3076967B1 (en) | 2013-12-03 | 2021-07-28 | Intra-Cellular Therapies, Inc. | Methods for treating residual symptoms of schizophrenia |
| CN105792824B (zh) * | 2013-12-13 | 2018-08-03 | 皮埃尔法布雷医药公司 | 色酮衍生物作为多巴胺d3受体拮抗剂用于治疗自闭症谱系障碍的用途 |
| US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3085366A1 (en) * | 2015-04-22 | 2016-10-26 | Institut du Cerveau et de la Moelle Epiniere-ICM | Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior |
| RU2743513C2 (ru) | 2016-01-26 | 2021-02-19 | Интра-Селлулар Терапиз, Инк. | Органические соединения |
| JP6686168B2 (ja) | 2016-03-25 | 2020-04-22 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| JP2019520315A (ja) * | 2016-04-29 | 2019-07-18 | スパーナス ファーマシューティカルズ インコーポレイテッド | 衝動的攻撃性を監視、診断、及び治療する方法、システム、及びキット |
| WO2018071233A1 (en) | 2016-10-12 | 2018-04-19 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| CN108210486B (zh) * | 2016-12-14 | 2020-05-19 | 陆汝斌 | 组合物用于制备治疗酒瘾或酒精滥用的药物的用途 |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP3562484B1 (en) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxaline derivatives useful in the treatment of cns disorders |
| MX387784B (es) | 2017-03-24 | 2025-03-18 | Intra Celular Therapies Inc | Composiciones novedosas y metodos. |
| IL272249B2 (en) | 2017-07-26 | 2023-11-01 | Intra Cellular Therapies Inc | Organic compounds |
| CA3071137A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | Prodrugs of substituted heterocycle fused gamma-carbolines |
| AU2018309710A1 (en) | 2017-08-01 | 2020-02-27 | Stuart A. Lipton | Methods and compositions for treating neurological conditions |
| US11447442B2 (en) | 2017-11-22 | 2022-09-20 | Panorama Research, Inc. | Aminoadamantyl nitrate compounds and their use to treat CNS disorders |
| CN112040940A (zh) | 2018-03-23 | 2020-12-04 | 细胞内治疗公司 | 有机化合物 |
| CA3102948A1 (en) | 2018-06-08 | 2019-12-12 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2020047241A1 (en) | 2018-08-29 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
| EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
| CA3108558A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| JP7377871B2 (ja) | 2018-12-21 | 2023-11-10 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP7649743B2 (ja) | 2018-12-21 | 2025-03-21 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| CN114072150A (zh) | 2019-07-07 | 2022-02-18 | 细胞内治疗公司 | 新方法 |
| US20240197652A1 (en) * | 2021-05-25 | 2024-06-20 | Awakn Ls Europe Holdings Limited | Ketamine in the treatment of behavioral addictions |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4994467A (en) * | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| US6387956B1 (en) * | 1999-03-24 | 2002-05-14 | University Of Cincinnati | Methods of treating obsessive-compulsive spectrum disorders |
| WO2001052851A1 (en) * | 2000-01-22 | 2001-07-26 | Albert Shulman | Methods for the treatment of substance abuse |
| US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
| AU2002354041A1 (en) * | 2001-11-06 | 2003-05-19 | John L. Haracz | Antimnemonic therapy for hypermemory syndromes |
| UY28650A1 (es) * | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
| US7456224B2 (en) * | 2004-04-05 | 2008-11-25 | Forest Laboratories Holdings, Ltd. | Method for treating autism |
-
2005
- 2005-09-19 EP EP05808933A patent/EP1793671B1/en not_active Expired - Lifetime
- 2005-09-19 AT AT05808933T patent/ATE506945T1/de not_active IP Right Cessation
- 2005-09-19 US US11/575,483 patent/US8461148B2/en not_active Expired - Fee Related
- 2005-09-19 AU AU2005286943A patent/AU2005286943A1/en not_active Abandoned
- 2005-09-19 ES ES05808933T patent/ES2367868T3/es not_active Expired - Lifetime
- 2005-09-19 WO PCT/US2005/033467 patent/WO2006034187A2/en not_active Ceased
- 2005-09-19 DE DE602005027714T patent/DE602005027714D1/de not_active Expired - Lifetime
- 2005-09-19 CA CA2580619A patent/CA2580619C/en not_active Expired - Fee Related
- 2005-09-19 DK DK05808933.5T patent/DK1793671T3/da active
- 2005-09-19 JP JP2007532585A patent/JP5289765B2/ja not_active Expired - Fee Related
-
2013
- 2013-06-07 US US13/912,408 patent/US20140088083A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008513491A (ja) | 2008-05-01 |
| CA2580619A1 (en) | 2006-03-30 |
| ES2367868T3 (es) | 2011-11-10 |
| US20140088083A1 (en) | 2014-03-27 |
| AU2005286943A1 (en) | 2006-03-30 |
| EP1793671A2 (en) | 2007-06-13 |
| WO2006034187A2 (en) | 2006-03-30 |
| EP1793671B1 (en) | 2011-04-27 |
| JP5289765B2 (ja) | 2013-09-11 |
| US20080249082A1 (en) | 2008-10-09 |
| ATE506945T1 (de) | 2011-05-15 |
| DE602005027714D1 (de) | 2011-06-09 |
| US8461148B2 (en) | 2013-06-11 |
| CA2580619C (en) | 2013-11-12 |
| EP1793671A4 (en) | 2008-03-12 |
| WO2006034187A3 (en) | 2006-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1793671T3 (da) | Anvendelse af memantin (namenda) til behandling af autisme, tvangstilstand og impulsivitet | |
| NL301145I2 (nl) | Tirbanibulin | |
| DK1651161T3 (da) | Farmaceutiske præparater og fremgangsmåder til at fremme sårheling | |
| NO20064124L (no) | Anvendelse av metformin og orlistat for behandling eller forebygging av fedme | |
| NO20071054L (no) | Metoder og blandinger for a modulere sfingosin-l-fosfat (sip) reseptoraktivitet | |
| EA200700333A1 (ru) | Терапевтические применения ингибиторов rtp801 | |
| EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
| CY1112238T1 (el) | Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων | |
| TW200602048A (en) | Diphenylimidazopyrimidine and -imidazole amines as inhibitors of β -secretase | |
| DE60235114D1 (de) | Pyrazolamide zur anwendung in der behandlung von schmerz | |
| DE60329789D1 (de) | Vorrichtung zur Verbesserung der Effizienz der Behandlung von Silicium | |
| EA200900021A1 (ru) | Пептидные соединения для лечения рефрактерного эпилептического статуса | |
| NO20075764L (no) | Kombinert anvendelse av prostaglandinforbindelse og protonpumpeinhibitor til behandling av forstyrrelser i mage- og tarmkanalen | |
| NO20060242L (no) | Kombinasjonen av en serotonin-reopptaksinhibitor og agomelatin | |
| NO20070914L (no) | Fremgangsmater for behandling av nervesystemforstyrrelser og tilstander | |
| EA200701995A1 (ru) | Способы уменьшения кальцификации | |
| NO20054913L (no) | Anvendelse av clustein for behandling og/eller forebyggelse av perifere nevrologiske lidelser | |
| NO20065859L (no) | Bruk av IL-17 behandlingen av fertilitetsrelaterte lidelser | |
| MXPA03010406A (es) | Tratamiento novedoso para el desorden obsesivo-compulsivo (ocd) y desordenes relacionados con ocd. | |
| DE602006013945D1 (de) | Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck | |
| NO20055563L (no) | Midler for behandlingen av lavere abdominale lidelser | |
| DK1853285T3 (da) | Fremgangsmåde til behandling af inflammation forbundet med amyloidaflejringer og hjerneinflammation som involverer aktiverede mikroglia | |
| EA200601871A1 (ru) | Способы лечения аутоиммунных и воспалительных заболеваний | |
| ATE536874T1 (de) | Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen | |
| ATE410235T1 (de) | Behandlung von ballastwasser |